R5XA Stock Chart & Stats
€1.06
-€0.09(-7.69%)
At close: 4:00 PM EDT
€1.06
-€0.09(-7.69%)
Day’s Range― - ―
52-Week Range€0.62 - €1.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€49.45M
Enterprise Value€67.22M
Total Cash (Recent Filing)€17.08M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Nov 16, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding51,905,796
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.67Price Target Upside151.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Registrational Trial ProgressAdvanced enrollment and activated trial sites reduce execution risk around the NEPHRO CRRT program and bring Talphera closer to a pivotal data readout. A timely, successful study could support the planned PMA filing and create a foundation for future commercialization.
Clinical And Guideline ValidationInclusion in draft KDIGO guidance provides external clinical validation for nafamostat and may improve awareness among nephrologists and treatment centers. Although positioned as an alternative to citrate, guideline recognition can support adoption if clinical and regulatory milestones are achieved.
Large And Established Market OpportunityA larger estimated U.S. procedure base expands the potential market for NEPHRO CRRT, while established nafamostat use overseas provides a commercial precedent. Existing physician familiarity may help reduce adoption barriers if the product gains approval.
Bears Say
Minimal Revenue And Persistent LossesThe current business is not generating meaningful revenue to support its cost base, leaving earnings highly dependent on future commercialization. Continued large losses could erode equity and require additional capital before any prospective product approval produces sustainable operating income.
Ongoing Cash Burn And Funding DependencePersistent operating and free-cash-flow deficits limit financial flexibility and make progress toward commercialization dependent on outside capital. Even with improved burn versus earlier periods, funding needs could pressure shareholders and constrain development if financing is delayed.
Regulatory And Financing Execution RiskThe anticipated approval path remains exposed to clinical timing, regulatory interactions, and financing conditions that Talphera does not fully control. Delays could extend losses, postpone commercialization, and increase the amount of capital required before the program reaches potential approval.
Talphera News
R5XA FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was €0.61 and its highest was €1.25 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is €49.45M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Nov 16, 2026 which is in 24 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Aug 12, 2026. The company reported -€0.053 earnings per share for the quarter, beating the consensus estimate of -€0.055 by €0.002.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.04.
How many shares outstanding does Talphera have?
Talphera has 51,905,796 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -€0.053 in its last earnings report, beating expectations of -€0.055. Following the earnings report the stock price went down -4.8%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in DE:R5XA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.30%
12-Months-Change
Fundamentals
Return on Equity
-87.28%
Trailing 12-Months
Asset Growth
62.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
R5XA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong clinical and commercial momentum: 75% enrollment in a registrational trial, positive DSMB feedback, KDIGO recognition of nafamostat, expanded market sizing (+21%), and encouraging dosing/titration data. Financially the company has runway assumptions but relies on conditional financing (~$16M) and faces modest near-term expense increases and regulatory timing uncertainty. On balance the achievements and favorable clinical/commercial signals outweigh the financing and timing risks.View all DE:R5XA earnings summariesR5XA Stock 12 Month Forecast
Average Price Target
€2.67
▲(151.99% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
Perrigo Company
―
Organogenesis Holdings
―
Evolus
―
Journey Medical Corp
―